BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Calvet X, Gisbert JP, Suarez D. Key points for designing and reporting Helicobacter pylori therapeutic trials: a personal view. Helicobacter. 2011;16:346-355. [PMID: 21923680 DOI: 10.1111/j.1523-5378.2011.00890.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Gisbert JP. Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract. 2012;2012:974594. [PMID: 22536225 DOI: 10.1155/2012/974594] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
2 Castro M, Romero C, de Castro A, Vargas J, Medina E, Millán R, Brenes M. Assessment of Helicobacter pylori eradication by virgin olive oil. Helicobacter. 2012;17:305-311. [PMID: 22759331 DOI: 10.1111/j.1523-5378.2012.00949.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
3 Georgopoulos SD, Xirouchakis E, Martinez-Gonzales B, Zampeli E, Grivas E, Spiliadi C, Sotiropoulou M, Petraki K, Zografos K, Laoudi F. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. Eur J Intern Med. 2016;32:84-90. [PMID: 27134145 DOI: 10.1016/j.ejim.2016.04.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
4 Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11:802-7.e1. [PMID: 23376004 DOI: 10.1016/j.cgh.2013.01.008] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 9.4] [Reference Citation Analysis]
5 Graham DY, Dore MP. Helicobacter pylori therapy demystified. Helicobacter. 2011;16:343-345. [PMID: 21923679 DOI: 10.1111/j.1523-5378.2011.00891.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
6 Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology. 2013;145:121-128.e1. [PMID: 23562754 DOI: 10.1053/j.gastro.2013.03.050] [Cited by in Crossref: 128] [Cited by in F6Publishing: 118] [Article Influence: 14.2] [Reference Citation Analysis]
7 Federico A, Nardone G, Gravina AG, Iovene MR, Miranda A, Compare D, Pilloni PA, Rocco A, Ricciardiello L, Marmo R. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology. 2012;143:55-61.e1; quize e13-4. [PMID: 22484118 DOI: 10.1053/j.gastro.2012.03.043] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
8 Salazar CO, Cardenas VM, Reddy RK, Dominguez DC, Snyder LK, Graham DY. Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter. 2012;17:382-390. [PMID: 22967122 DOI: 10.1111/j.1523-5378.2012.00962.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
9 Zhou L, Zhang J, Chen M, Hou X, Li Z, Song Z, He L, Lin S. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. Am J Gastroenterol. 2014;109:535-541. [PMID: 24642580 DOI: 10.1038/ajg.2014.26] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 7.0] [Reference Citation Analysis]
10 Shmuely H, Domniz N, Yahav J. Non-pharmacological treatment of Helicobacter pyloriWorld J Gastrointest Pharmacol Ther 2016; 7(2): 171-178 [PMID: 27158532 DOI: 10.4292/wjgpt.v7.i2.171] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]